Elanco Animal Health has released its financial report for both the final three months, and the entire year of 2022, together with preliminary forecasts for the first sixth months and entire of this year.

It has been revealed that for 2022’s Q4, Elanco produced a huge $988m in sales, but also had a total loss of $55m.

“Elanco Animal Health has released its financial report for Q4 2022“

Moving into 2023 their predictions are for sales revenue to increase by a minimum of 333%, to between $4,280m and $4,400m.

Although, they also expect total loss to increase at least 185% to between $(157m) and $(109m).

Elanco is in the process of introducing a number of new products to market in the near future, having completed the first stages of getting their JAK Inhibitor signed off by the US FDA.

They predict the process will be finalised before the summer of 2024.

The company has already obtained a sign off for their Bexacat product, which is currently the only SGLT-2 inhibitor for cat diabetes on the market. They are also ready to re-release two over the counter parasiticides- one for cats and one for dogs, both having received clearance by the US EPA.

Finally, Elanco has also revisited forecasts for their Bovaer cattle food ingredient which minimises methane production. They now anticipate this to be cleared for market by summer 2024.

© Copyright 2010-2021 Zenopa LTD. All Rights Reserved.